文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

骨肉瘤、软骨肉瘤和脊索瘤的IG-IMRT治疗结局

Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy.
PubMed 文献 · Radiother Oncol · 2021-09-28

这项前瞻性非随机研究纳入65例头颈或骨盆的骨肉瘤、软骨肉瘤和脊索瘤患者,接受剂量递增的IG-IMRT。5年局部控制率分别为66%、38.1%和75.9%,死因特异性生存率分别为54.7%、64.3%和92.2%,急性≥3级毒性3%,晚期≥3级毒性0%。

要点

  • 剂量递增IG-IMRT在骨肉瘤、软骨肉瘤和脊索瘤中局部控制良好且毒性低。
  • 脊索瘤5年局部控制率75.9%,死因特异性生存率92.2%。
  • 放疗后MSTS评分显著持续改善,疼痛评分降低。

核心结论

  • 剂量递增IG-IMRT在骨肉瘤、软骨肉瘤和脊索瘤中取得良好局部控制和功能改善,毒性极小。

主要发现

  • 61例(93.8%)完成计划放疗,急性≥3级毒性3%,晚期≥3级毒性0%。
  • 中位随访52个月(范围6-92),5年局部控制率骨肉瘤66%、软骨肉瘤38.1%、脊索瘤75.9%。
  • 5年死因特异性生存率骨肉瘤54.7%、软骨肉瘤64.3%、脊索瘤92.2%。
  • 根治性与术后放疗 outcomes 无统计学显著差异。
  • 放疗后首次随访局部控制与软骨肉瘤(p=0.014)和脊索瘤(p<0.001)的死因特异性生存及总生存改善相关。

关键数值与推荐

  • 根治性放疗剂量:脊索瘤72.0 Gy,骨肉瘤和软骨肉瘤70.2 Gy;术后放疗剂量:脊索瘤66.6 Gy,骨肉瘤和软骨肉瘤64.8 Gy(每次1.8 Gy)。
  • 放疗后MSTS评分显著持续改善,疼痛评分降低。
  • 局部进展后 salvage 再照射可行,结局和耐受性良好。

临床怎么用

  • 对头颈或骨盆骨肉瘤、软骨肉瘤和脊索瘤可考虑剂量递增IG-IMRT,以改善局部控制和功能并降低毒性。
  • 放疗后首次随访局部控制与软骨肉瘤和脊索瘤生存改善相关,应重视早期疗效评估。
  • 局部进展后可考虑 salvage 再照射,但需评估可行性和耐受性。

局限性

  • 前瞻性非随机研究,样本量较小(65例),软骨肉瘤仅7例。
  • 随访时间有限,中位52个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & PURPOSE: To evaluate the efficacy and toxicity of dose-escalated image guided-intensity modulated radiation therapy (IG-IMRT) in osteosarcoma (OGS), chondrosarcoma (CS) and chordoma (CH) of head and neck (H&N) and pelvis. METHODS AND MATERIALS: In this prospective non-randomized study, 65 patients of H&N or pelvic OGS (24), CS (7) and CH (34) mandating definitive or post-operative radiotherapy from May 2013 to December 2018 were included. Radiotherapy doses in definitive setting were 72.0 Gy for CH and 70.2 Gy for OGS and CS; while in post-operative setting it was 66.6 Gy and 64.8 Gy respectively (at 1.8 Gy per fraction). RESULTS: Planned doses of radiotherapy could be completed in 61 (93.8%) patients; with grade III or higher acute and late toxicities of 3% and 0% respectively. With a median follow-up of 52 (range 6-92) months, the five-year actuarial local control (LC) rates were 66% in OGS, 38.1% in CS and 75.9% in CH; while cause-specific survival (CSS) rates were 54.7%, 64.3% and 92.2% respectively. There was no statistically significant difference in outcomes for patients receiving definitive and post-operative radiotherapy. Locally controlled disease at first follow-up after radiotherapy was associated with improved CSS and OS in CS (p = 0.014) and CH (p < 0.001). Radiotherapy resulted in significant and sustained improvement in Musculoskeletal tumour society (MSTS) score and reduction in pain score. Salvage re-irradiation was feasible in local progression after radiotherapy, with good outcomes and tolerability. CONCLUSION: Dose-escalated IG-IMRT results in good LC & functional improvement with minimal toxicity in OGS, CS and CH.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Laskar S, Kakoti S, Khanna N, et al. Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy. Radiother Oncol. 2021. PMID: 34597737. doi:10.1016/j.radonc.2021.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。